Increased IL6 Transcription by HHV8
Increased IL6 Transcription by HHV8
批准号:
7022276
负责人:
MATTHEW B RETTIG
金额:
$22.73万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-03-15 至 2008-02-28
关键词:
Herpesviridae diseaseantisense nucleic acidapoptosisclinical researchgene induction /repressiongenetic promoter elementgenetic transcriptionhost organism interactionhuman herpesvirus 8human subjectimmunogeneticsinterleukin 6microorganism immunologyprotein protein interactiontranscription factorvirus antigenvirus geneticsvirus protein
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (provided by applicant) The human herpesvirus 8 (HHV8) has been
associated with three neoplasms: primary effusion lymphoma, Kaposi's sarcoma,
and multicentric Castleman' s disease in human immunodeficiency virus
(HIV)-related and -unrelated cases. In addition, there is evidence that HHV8
may be present in the bone marrow of multiple myeloma patients. While HHV8 is
not ubiquitous in the general population (10-15 percent seroprevalence),
evidence of exposure to HHV8 is quite high (60-70 percent) in the homosexual
HIV-positive population. One common feature amongst all HHV8-associated
neoplasms is that they utilize interleukin 6 (IL-6) as a tumor growth factor.
IL-6 may also facilitate HIV infection, as it induces the proliferation of HTV
in HIV infected monocytes and CD4-positive T cells. Thus, we initially
hypothesized that an HFIV8 encoded protein upregulates IL-6 expression.
In preliminary data we successfully demonstrated that the HHV8 latent proteins,
latency associated nuclear antigen (LANA) and Fas associated death domain like
interferon converting enzyme inhibitory protein (vFLIP), upregulate cellular
IL-ti expression. We have shown that LANA transactivates the IL-6 promoter
through the API response element, LANA directly binds to the APi response
element, and vFLIP functions through activation of the NF-kappaB and APi
transcription factors. Furthermore, vFLIP potentiates LANA-induced IL-6
expression and vice versa.
In this proposal, our specific aims are: 1. Elucidate the relevant DNA-protein
interactions involved in LANA-mediated transactivation of the LL-6 promoter. 2.
Identify the protein-protein interactions involved in LANA transactivation of
the IL-6 promoter. 3. Establish the importance of vFLIP and LANA in the
induction of IL-6 expression as well as proliferation and inhibition of
apoptosis in endogenously HHVS-infected cells, and characterize the molecular
interactions between vFLIP and LANA that result in their reciprocal
potentiation of IL-6 induction.
Our long-term objective is to identify the molecular mechanisms involved in
HHVS -mediated upregulation of cellular IL-6 production. The identification of
the specific domains of LANA or vFLIP that are involved in the augmentation of
IL-ti expression might provide a natural target for drug development to inhibit
the effects of these proteins in HHV8 infected malignant cells.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
-
批准号:10917011
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:MATTHEW B RETTIG
-
依托单位:
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
-
批准号:10417047
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:MATTHEW B RETTIG
-
依托单位:
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
-
批准号:9487898
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MATTHEW B RETTIG
-
依托单位:
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
-
批准号:8921769
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:8551641
-
项目类别:
-
资助金额:$24.58万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:9097575
-
项目类别:
-
资助金额:$26.15万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:8699713
-
项目类别:
-
资助金额:$25.36万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:8912402
-
项目类别:
-
资助金额:$26.15万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:8373260
-
项目类别:
-
资助金额:$26.15万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
-
批准号:8413407
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:MATTHEW B RETTIG
-
依托单位:
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
-
批准号:7927183
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:MATTHEW B RETTIG
-
依托单位:
Targeting Androgen Receptor Activity in Prostate Cancer
-
批准号:7030446
-
项目类别:
-
资助金额:$9.44万
-
财政年份:2006
-
负责人:MATTHEW B RETTIG
-
依托单位:
Targeting Androgen Receptor Activity in Prostate Cancer
-
批准号:7229925
-
项目类别:
-
资助金额:$9.17万
-
财政年份:2006
-
负责人:MATTHEW B RETTIG
-
依托单位:
Increased IL6 Transcription by HHV8
-
批准号:6430782
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Increased IL6 Transcription by HHV8
-
批准号:6726106
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Project 2: Developing an N-terminal inhibitor of the androgen receptor
-
批准号:10000845
-
项目类别:
-
资助金额:$27.18万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Project 2: Developing an N-terminal inhibitor of the androgen receptor
-
批准号:10704572
-
项目类别:
-
资助金额:$24.61万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Project 2: Developing an N-terminal inhibitor of the androgen receptor
-
批准号:10478982
-
项目类别:
-
资助金额:$30.33万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Project 2: Developing an N-terminal inhibitor of the androgen receptor
-
批准号:10246998
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Increased IL6 Transcription by HHV8
-
批准号:6621178
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
海外基金